Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In the univariate analysis, age, gender, disease duration, BMI, smoking status, vitamin D level, prior use of DMT, number of prior relapses, and number of NTZ infusions were not associated with the risk of disease reactivation after NTZ was discontinued.

Source: Disease Reactivation after NTZ Discontinuation. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were selected only if they had clinical and radiological data available for at least 12 months after their last infusion.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri)

Study design awaiting verification · Brain and Behavior · 2025

Original publication title

Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri)

Roba El Zibaoui; Nabil K. El Ayoubi; Samia J. Khoury

© 2025 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Conclusion:

NTZ discontinuation requires thorough clinical evaluation for bridging therapy, yet optimal strategies remain undefined. Early bridging therapy initiation may mitigate reactivation, highlighting the need for further research on predictive factors and disease‐modifying therapy efficacy.

An extract from the source publication. Read it in context.

At a glance

Abstract: What methods does the paper describe?

In this retrospective single‐center study, 171 patients with RRMS who received at least six consecutive NTZ infusions were analyzed. Clinical and radiological data were sourced from the AMIR registry. Binary and multivariate regression analyses were performed to identify factors associated with reactivation risk after 1 year, with a subset undergoing brain magnetic resonance imaging (MRI) segmentation and volumetric assessments.

Source: Methods

Abstract: Results

Among 92 eligible patients, 16 (17%) showed disease reactivation. Prolonged washout periods (>3 months) significantly increased reactivation risk (hazard ratio [HR] 1.015, 95% CI 1.007 to 1.022, p < 0.001), whereas higher Expanded Disability Status Scale (EDSS) scores correlated with a reduced risk (HR 0.492, 95% CI 0.280 to 0.866, p < 0.014). In the subset of cases that underwent brain MRI segmentation, higher NTZ infusion numbers and delayed bridging therapy initiation were linked to increased reactivation risk.

Source: Results

Abstract: Conclusion

NTZ discontinuation requires thorough clinical evaluation for bridging therapy, yet optimal strategies remain undefined. Early bridging therapy initiation may mitigate reactivation, highlighting the need for further research on predictive factors and disease‐modifying therapy efficacy.

Source: Conclusion
Authors’ abstract

ABSTRACT

Background and Purpose: Natalizumab (NTZ) is widely used for patients with highly active relapsing: remitting multiple sclerosis (RRMS), but its discontinuation can lead to disease reactivation, significantly impacting Middle Eastern populations. This study aimed to assess the frequency of disease reactivation post‐NTZ discontinuation and identify possible demographic predictors.

Methods:

In this retrospective single‐center study, 171 patients with RRMS who received at least six consecutive NTZ infusions were analyzed. Clinical and radiological data were sourced from the AMIR registry. Binary and multivariate regression analyses were performed to identify factors associated with reactivation risk after 1 year, with a subset undergoing brain magnetic resonance imaging (MRI) segmentation and volumetric assessments.

Results:

Among 92 eligible patients, 16 (17%) showed disease reactivation. Prolonged washout periods (>3 months) significantly increased reactivation risk (hazard ratio [HR] 1.015, 95% CI 1.007 to 1.022, p < 0.001), whereas higher Expanded Disability Status Scale (EDSS) scores correlated with a reduced risk (HR 0.492, 95% CI 0.280 to 0.866, p < 0.014). In the subset of cases that underwent brain MRI segmentation, higher NTZ infusion numbers and delayed bridging therapy initiation were linked to increased reactivation risk.

Conclusion:

NTZ discontinuation requires thorough clinical evaluation for bridging therapy, yet optimal strategies remain undefined. Early bridging therapy initiation may mitigate reactivation, highlighting the need for further research on predictive factors and disease‐modifying therapy efficacy.

Publication and source details

Original title: Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri)

Roba El Zibaoui; Nabil K. El Ayoubi; Samia J. Khoury

Brain and Behavior · 2025

© 2025 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:07:08.305538+00:00

DOI: 10.1002/brb3.70904 · PMC12451047